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INTRODUCTION
Stem and progenitor cells required for engraftment and
recovery of hematopoiesis after blood stem cell transplanta-
tion express the CD34 cell surface antigen. An adequate
dose of CD34 cells is likely required to ensure early and
sustained hematopoietic recovery. Although there is no uni-
versal agreement on the optimal CD34 cell dose for trans-
plantation, recent data suggest that a dose response exists
between the number of CD34 cells infused and recovery of
platelets. The risk of delayed recovery is inversely related to
CD34 cell dose. Rapid recovery is consistently attained
when CD34 cell doses 5106 CD34 cells/kg are infused,
and thus represents a reasonable target for collection. In this
paper we review available literature on hematopoietic cell
dose and provide an overview of ﬁndings on the subject. 
Historically, mononuclear cell (MNC) counts and
colony-forming units granulocyte-macrophage (CFU-GM)
have been used to assess the adequacy of hematopoietic cell
transplants. Yields of CD34 cells and CFU-GM colonies in
the harvest generally have correlated well with each other
[1–17]. A relationship between CFU-GM colonies and time
to hematologic recovery has been demonstrated in most
[7,9,12,16,18–20] but not all studies [15,21]. Similarly, some
studies report a correlation between MNCs and time to
recovery, while others do not [9,13,16,21,22].
CD34 cell content as surrogate endpoint
More recently, the number of cells expressing CD34
has been used to assess peripheral blood progenitor cell
(PBPC) graft quality. CD34 is an antigen expressed on
early uncommitted and committed progenitor cells. In 1991,
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ABSTRACT
The CD34 cell surface antigen is expressed on progenitor cells required for blood stem cell transplantation. The
number of cells expressing CD34 can be used to assess the peripheral blood progenitor cell (PBPC) graft quality
and predict hematopoietic recovery after engraftment. Because there is considerable variability among centers in the
determination of CD34 cell counts, standardizing flow cytometry methodology is essential. It is necessary to define
a minimum safety threshold CD34 cell dose for hematopoietic cell transplantation. This minimum dose would
define a cell number in the graft, below which a proportion of patients would be expected to have delayed hemato-
poietic recovery or failure to engraft. We reviewed data from numerous studies. Although 1–2106 CD34 cells/kg
can be considered an adequate graft, available data suggested that doses 5106 CD34 cells/kg were associated
with more rapid engraftment and a lower probability of graft failure. The risk of delayed recovery was inversely
related to CD34 cell dose. Delayed recovery may result in greater transfusion requirements, longer hospitalization,
increased antibiotic use and growth factor support, and higher health care costs. The extent of prior chemotherapy
and radiation treatment are major risk factors for poor PBPC collection. To achieve an optimal CD34 cell yield,
PBPC collection should be initiated early during therapy. PBPC collection should be coordinated with the anticipat-
ed number of chemotherapy cycles, duration of chemotherapy, interval between chemotherapy and apheresis, need
for radiotherapy, and exposure to the more progenitor cell–toxic drugs such as carmustine or busulfan.
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Siena et al. suggested that the infused CD34 PBPC dose
could be used as a predictor of hematopoietic recovery after
engraftment [14]. Since then, a direct correlation between
the number of collected or infused CD34 cells/kg and the
rapidity of hematologic recovery has been identified by
many investigators. The CD34 cell dose has a more pro-
found effect on recovery of platelets than of granulocytes
[2,4–11,13,16,17,23–33]. It should be noted that, in this
review, CD34 cell number is used as a surrogate marker for
sources from peripheral blood; extrapolation to other cell
sources (e.g., cord blood, bone marrow, or ex vivo-expanded
cells) may not be appropriate.
The percentage of CFU-GM or CD34 cells may vary
greatly within the MNC preparations between patients and
within different harvests from the same patient. For these rea-
sons, many investigators have found a poor correlation
between MNC count and engraftment kinetics [9,13,16,21,22]
or between the MNC content in blood or harvest and the
CD34 cell count in the harvested apheresis product [4,10].
The CD34 cell analysis is performed by ﬂow cytome-
try. Results can be obtained rapidly, within the same day of
the PBPC collection, as opposed to the CFU-GM assay,
which requires 10–14 days before it can be interpreted.
Moreover, there is great variability in the factors and media
used for stimulating colony growth and the inconsistent
results between laboratories with the CFU-GM assay. 
Standardization of CD34 cell analysis
Because the CD34 cell fraction is a small percentage of
MNCs, small variations in ﬂow cytometric techniques can
lead to large variations in the number of CD34 cells enu-
merated from a given sample. Hence, there is a need to stan-
dardize the methodology so that results from different cen-
ters can be compared. The method of processing the aphere-
sis sample affects the amount of cell debris and red blood cell
contamination. The anti-CD34 antibody and the fluo-
rochrome label used affects the speciﬁcity and sensitivity of
immunolabeling. The gating strategy, including the denomi-
nator for the number of CD34 cells, is critical in determin-
ing the frequency of CD34 cells in the PBPC graft [34].
There is considerable variability among centers in the deter-
mination of CD34 cells. This confounds and greatly com-
plicates considerations of optimal CD34 cell doses. 
Obviously, the more reproducible a CD34 cell assay, the
more likely the CD34 cell number will correlate consistent-
ly with engraftment. Moreover, center-to-center variations in
CD34 cell enumeration in a given sample, based on differ-
ences in gating strategy [35], impedes the ability to compare
engraftment conditions of different centers and hence the
development of national standards for graft quality. 
To standardize CD34 analyses, we recommend flow
cytometric methods consistent with those developed by Dr.
R. Sutherland and the International Society for Hematology
and Graft Engineering [36].
CD34 subset analysis
Stem cells responsible for engraftment probably repre-
sent a small fraction of the CD34 subsets. Analyses of these
subsets have been performed to identify more precise mark-
ers for neutrophil and platelet engraftment. Progenitors that
are CD34CD33 have been reported to correlate signiﬁ-
cantly better than the total number of CD34 cells with
respect to time to neutrophil recovery in some studies [27].
Similarly, CD34CD41 cells were a better predictor of time
to platelet recovery than CD34 cells alone [27]. Dercksen et
al. reported a relationship between CD34 L-selectin cell
dose and platelet recovery after peripheral blood stem cell
transplantation using chemotherapy and granulocyte colony-
stimulating factor (G-CSF) mobilization therapy [37]. Stud-
ies evaluating CD34CD33, CD34CD38, and
CD34Thy-1 subpopulations are also in progress [38].
While these attempts to reﬁne our ability to gauge the poten-
tial of a given graft to support rapid engraftment have
promise, the total number of CD34 cells is currently the
best measure feasible for wide use.
Stem cell dose and time to hematologic recovery
There is a need to define a minimum safety threshold
CD34 cell dose for hematopoietic cell transplantation. This
minimum dose would deﬁne a cell number in the graft, below
which an unacceptable proportion of patients would be expect-
ed to have delayed hematopoietic recovery or failure to engraft.
In 1996, Laport et al. reported engraftment kinetics for
two groups of patients undergoing PBPC transplantation
[29]. Eighteen patients reinfused with 1106 CD34
cells/kg achieved neutrophil recovery (absolute neutrophil
count [ANC] 500106/L) in 11 days compared with 18
patients reinfused with 1106 CD34 cells/kg who expe-
rienced a 2-day delay in neutrophil recovery (13 days).
However, platelet engraftment appeared much more sensi-
tive to cell dose. Median platelet recovery (to 20109/L)
occurred on day 28 for those reinfused with 1106
CD34 cells/kg. For those reinfused with 1106 CD34
cells/kg, seven patients reached platelet recovery at a median
of 158 days and two patients had not achieved platelet inde-
pendence by day 90 posttransplant. Nine patients in their
study died without achieving platelet transfusion indepen-
dence; the posttransplant day at which death occurred was
not reported. Laport et al. also evaluated the effects of rein-
fusing 2106 CD34 cells/kg and found that the median
platelet recovery time decreased from 28 to 17 days with no
significant effect on neutrophil recovery time. They con-
cluded that a CD34 cell dose 2106 more consistently
produced rapid platelet recovery.
Several studies have reported the time to engraftment as
a function of the number of CD34 cells/kg infused. Data
from studies in which 2106 (Table 1) and 2.5106 CD34
cells/kg (Table 2) were used as doses above and below which
engraftment occurred are summarized below.
These studies demonstrated a 2- to 4-day improvement
in neutrophil recovery for patients who received 2106
CD34 cells/kg compared with those who received 2106.
Similar improvements were recorded for patients who
received 2.5106 CD34 cells/kg compared with those
who received 2.5106.
The most striking impact of higher CD34 cell numbers
occurred with time to platelet recovery. Patients who received
2106 CD34 cells/kg engrafted platelets at a median of
12–15 days and experienced a 9- to 60-day improvement in
time to platelet recovery compared with those who received
2106 CD34 cells/kg and engrafted platelets from day 21
to 75. Similarly, patients who received 2.5106 CD34
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cells/kg engrafted platelets from day 9 to 14, and experienced
a 3- to 17-day improvement in platelet recovery compared
with those who received 2.5106 CD34 cells/kg and
engrafted platelets from day 12 to 31.
Using 2.0 or 2.5106 CD34 cells/kg as the target, we
noted that patients who received more than the designated
minimal target had a much tighter range of time to platelet
recovery than did patients who received less than the desig-
nated target.
Many of the studies summarized had a small sample size,
and most did not report the ranges for engraftment times.
This is an important issue with respect to interpreting the
available literature. It is possible that severely delayed
engraftment or graft failure is the most important result of
inadequate CD34 cell dosing. A substantial increase in the
risk of inadequate engraftment may not affect the median
time to engraftment until the failure rate exceeds 50%.
Hence, medians should always be accompanied by ranges,
and details regarding patients who have not achieved
engraftment by the cutoff time should be given. Otherwise,
studies may under-estimate the sequelae of inadequate
CD34 cell dosing.
Other investigators have reported delayed platelet
recovery in patients who have received 2106 CD34
cells/kg. Tricot et al. reported that approximately 12% of
patients did not meet the criteria for platelet engraftment by
day 21, despite a CD34 cell dose of 2106/kg [33]. In
their study, when patients received a CD34 cell dose
5106/kg, 93% engrafted platelets by day 21, whereas
only 69% of patients who received 2 to 5106 CD34
cells/kg did so. Similarly, in the study reported by Schiller et
al., all 37 patients achieved neutrophil recovery by day 16
[31]. However, 34 patients achieved platelet recovery at a
median of 12 days after transplantation but, based on ranges
provided, some did not achieve platelet recovery until day
52. Moreover, three patients died on days 28, 38, and 52
without achieving platelet engraftment. In the study by
Haynes et al., some patients reinfused with 2.5106
CD34 cells/kg did not achieve neutrophil and platelet
recovery until days 17 and 40, respectively [6]. 
Table 1. Hematologic recovery as a function of CD34 cell counts  and 2106/kg
106 CD34 cells/kg Time to neutrophil recoverya Time to platelet recoveryb
Author [reference] (nnumber of patients) (days) (days)
Boroson et al. [25] 2 (n21) 11 (NA) (p  0.0003) 12 (NA) (p  0.0005)
2 (n11) 15 (NA) 23 (NA)
Schiller et al. [31] 2 (n31) 12 (NA) (p  0.05) 12 (NA) (p  0.001)
2 (n6) 14 (NA) 21 (NA)
Tricot et al. [33] 2 (n188) 11 (NA) (p  0.0001) 12 (NA) (p  0.0001)
2 (n37) 13 (NA) 52 (NA)
Zimmerman et al. [17] 2 (n10) 12 (8–15)c 15 (10–47) (p  0.05)
2 (n12) NA (9–28) 75 (10–674)
aNeutrophil recovery is deﬁned as the median [17,25,31] or mean [33] number of days from reinfusion to reach an absolute neutrophil count of 500106/L.
Numbers in parentheses are the range.
bPlatelet recovery is deﬁned as the median [17,25,31] or mean [33] number of days required to reach a platelet count of 20109/L [25,31] or 50109/L [17,33]
without transfusion support. Numbers in parentheses are the range.
cp not provided. 
NA, not available.
Table 2. Hematologic recovery as a function of CD34 cell counts  and 2.5106/kg
106 CD34 cells/kg Time to neutrophil recoverya Time to platelet recoveryb
Author [reference] (nnumber of patients) (days) (days)
Haas et al. [5] 2.5 (n35) Within 2 weeks in all patientsc Within 2 weeks in all patients except onec
2.5 (n7) 17 (11–34) 31 (13–141)
Haynes et al. [6] 2.5 (n24) 12.5 (9–17) (p  0.0025) 12 (8–40) (p  0.0016)
2.5 (n14) 16 (11–26) 26 (11–118)
Papadopoulos et al. [9] 2.5 (n16) 8 (7–11) (p  0.007) 9 (8–14) (p  0.006)
1–2.5 (n15) 9 (8–11) 12 (8–15)
Schwella et al. [13] 2.5 (n17) 9 (7–10) (p  0.0002) 10 (7–14) (p  0.007)
2.5 (n7) 12 (10–13) 15 (9–24)
aNeutrophil recovery is deﬁned as the median number of days from reinfusion to reach an absolute neutrophil count of 500106/L. Numbers in parentheses are the
range.
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Several studies have compared results from patients rein-
fused with cell doses 5106 and 5106 CD34 cells/kg.
These data are presented in Table 3.
In a study by Hohaus et al., four patients reinfused with
5106 CD34 cells/kg achieved platelet recovery within
8–12 days, whereas five patients treated with 5106
CD34 cells/kg had platelet recovery delayed from 30 to 42
days [39]. Bensinger et al. reviewed data from 243 patients
undergoing PBPC transplantation [24]. Patients were divid-
ed into three groups based on reinfused CD34 cell counts:
5106, 2.5–5106, and 2.5106 CD34 cells/kg.
Results indicated a significant difference in neutrophil
recovery between the higher CD34 cell dose groups and
the lowest dose group. However, there was no significant
difference in neutrophil recovery between patients receiving
5106 CD34 cells/kg and those receiving 2.5–5106
CD34 cells/kg. Relatively little data regarding the speciﬁcs
of platelet engraftment outcomes as a function of CD34
cell dose were provided. However, there was a significant
difference among all groups with platelet recovery inversely
related to cell dose. Long-term failure to recover throm-
bopoiesis was substantially more frequent in patients receiv-
ing 5106 cells/kg compared with those receiving
5106 cells/kg. Speciﬁcally, 4.6% of patients treated with
5106 CD34 cells/kg died between days 1 and 112 with-
out reaching platelet independence; 17.6% of patients treat-
ed with 5106 CD34 cells/kg died between days 3 and
394 without attaining platelet transfusion independence.
In a study of 215 breast cancer patients receiving identi-
cal high-dose chemotherapy (HDCT) and supportive care
Table 3. Hematologic recovery as a function of CD34 cell counts  and 5106/kg a
106 CD34 cells/kg Time to neutrophil recoveryb Time to platelet recoveryc
Author [reference] (nnumber of patients) (days) (days)
Kiss et al. [7] 5 (n10) 10 (8–10) (p  0.002) 9 (8–12) (p  0.004)
5 (n7) 11 (10–14) 21 (11–NR)
Sola et al. [32] 5 (n16) 8 (7–9) (p  0.0002) 8 (7–9) (p  0.001)
5 (n18) 9.5 (8–10) 11.5 (9–14)
van der Wall et al. [16] 5 (n15) 9 (8–12) (p  0.0001) 12 (7–37) (p  0.0012)
5 (n15) 11 (10–13) 21 (15–40)
Weaver et al. [41] 0.5–2.5 (n15) 11 (9–28) (p  0.05) 12 (6–32) (p  0.05)
2.5–5 (n135) 10 (5–26) 11 (0–53)
5.0–7.5 (n112) 10 (7–32) 10 (0–31)
7.5–10 (n84) 9 (7–32) 10 (4–21)
10–12.5 (n57) 9 (5–16) 10 (5–24)
12.5 (n289) 8 (5–15) 8 (0–22)
aBensinger et al. [24] and Hohaus et al. [39] also showed hematologic recovery as a function of CD34 cell counts  and 5106/kg (data not shown; see text).
bNeutrophil recovery is deﬁned as the median number of days from reinfusion to reach an absolute neutrophil count of 500106/L. 
cPlatelet recovery is deﬁned as the median number of days required to reach a platelet count of 20109/L without transfusion support.
NR, not recovered.
Figure 1. Cox proportional hazards analysis for probability of engraftment to platelets 20109/L, with the yield of CD34 cells as the
predictor (n212)
Reproduced with permission from Glaspy et al. [40].
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(in which centralized CD34 cell enumeration was used),
engraftment and CD34 cell numbers were used to con-
struct a Cox proportional hazards model (Figure 1) [40].
The model predicts that patients receiving an infusion of
5106 CD34 cells/kg will have an 85% probability of
platelet engraftment to 20109/L by day 14 posttransplant
and a very low incidence of delayed platelet recovery beyond
28 days. The model predicts that the infusion of 5106
CD34 cells/kg will be associated with a lower probability
of rapid platelet engraftment. For instance, the infusion of
2106 CD34 cells/kg would be associated with a 65%
probability of platelet engraftment by day 14, with approxi-
mately 10% of patients predicted to have delayed platelet
recovery beyond day 28.
Again, because these studies have had relatively small
sample sizes, they have shown signiﬁcantly shorter mean or
median times to neutrophil and platelet engraftment for
patients receiving 5106 CD34 cells/kg. Although
speciﬁcs are not given, reported ranges for times to platelet
recovery suggest that fewer patients have delayed platelet
engraftment when doses 5106 CD34 cells/kg are used.
Less data are available on the effects of even higher
CD34 cell doses. Dercksen et al. analyzed data from 59
patients and found that CD34 cell doses of 10106 cells/kg
compared with 2.5106 cells/kg were associated with
improved neutrophil recovery by 1–2 days and platelet
recovery from 17 to 11 days, respectively [27]. The authors
concluded that a CD34 cell dose of at least 10106 might
result in fewer days of neutropenia and fewer platelet trans-
fusion days compared with a dose of 2.5106 CD34
cells/kg. Weaver et al. evaluated data from 692 patients to
assess the 95% probability of time to neutrophil and platelet
recovery as a function of CD34 cell dose [41]. Patients had
a 95% probability of neutrophil and platelet recovery by
days 15 and 20, respectively, when the CD34 cell dose was
5106/kg. At doses 7.5106 CD34 cells/kg, there was
a 95% probability of neutrophil recovery by day 13. Weaver
et al. concluded that 5106 CD34 cells/kg is an optimal
number of stem cells for transplantation. 
Clearly, the doses of CD34 cells being examined as opti-
mal targets in PBPC support of HDCT are increasing as a bet-
ter understanding develops of the association between CD34
cell dose and both median engraftment times and the risk of
severely delayed engraftment. Although 1–2106 CD34
cells/kg can still be considered an adequate graft, available data
suggest that doses 5106 are associated with more rapid
engraftment and a lower probability of graft failure. These data
must be balanced by the cost and logistical difﬁculties in col-
lecting large numbers of CD34 cells with standard mobiliza-
tion procedures. Nonetheless, CD34 cell doses 5106/kg
currently should be considered the optimal target dose.
Reduced transfusion requirements
Patients experiencing more rapid engraftment would like-
ly consume fewer healthcare resources, including hospitaliza-
tion, antibiotic use, post-HDCT cytokine use, home nursing
care, and transfusions. The literature on the relationship of
CD34 cell dose to transfusion requirements is summarized in
Table 4. In most studies, higher CD34 cell doses have been
associated with signiﬁcantly reduced platelet requirements. In
some studies, usually those incorporating larger numbers of
patients, higher CD34 cell doses also have been associated
with decreased red blood cell transfusion requirements. This
may be due to the greater statistical power of the larger stud-
ies. It is unclear whether the decreased red blood cell transfu-
sion requirements represent more rapid recovery of erythro-
poiesis or decreased microscopic bleeding associated with
thrombocytopenia. Note that many of the studies cited here
provided median transfusion numbers. As stated above, these
numbers may not reveal the impact of lower CD34 cell doses
on outlier risk, and thus are likely to underestimate the impact
of a lower dose on resource consumption. 
CD34 cell yields in hard-to-mobilize patients
Impact of time interval from chemotherapy and number of
chemotherapy cycles. Several investigators have speciﬁcally
addressed the effects of CD34 cell doses on hematopoietic
recovery in hard-to-mobilize patients. In 1991, Shepherd et
al. first reported that, in patients with hematologic
malignancies who had bone marrow involvement and prior
chemotherapy within 12 months of PBPC transplant, there
was an associated decrease in mobilization [42]. Haas et al.
found that, in patients with malignant lymphoma, a shorter
time interval from chemotherapy to apheresis as well as a
history of prior radiotherapy affected the efficiency of the
CD34 cell yields [5]. For each cycle of chemotherapy in
patients not receiving irradiation, they calculated that the
CD34 cell yield per apheresis decreased by an average of
Table 4. Platelet and RBC transfusions as a function of CD34 cell counts
106 CD34 cells/kg Number of Number of
(n=number platelet RBC
Author [reference] of patients) transfusionsa transfusionsa
Laport et al. [29] 1 (n18) 1 (p  0.003) 1 (p  0.04)
1 (n18) 3 1.7
Boroson et al. [25] 2 (n21) 5 (NS) 6 (NS)
2 (n11) 8 5
Schiller et al. [31] 2 (n31) 2 (p  0.002) 6 (p  0.005)
2 (n6) 30 19
Haas et al. [5] 2.5 (n35) 4b NA
2.5 (n7) 13 NA
Haynes et al. [6] 2.5 (n24) 1.7 (p  0.048) 0.7 (p  0.04)
2.5 (n14) 4.2 1.2
Papadopoulos et al. [9] 2.5 (n16) 3 (p  0.061) 0.3 (p  0.37)
1–2.5 (n15) 5 0.3
Remes et al. [10] 4 (n26) 1.3 (p  0.043) 0.3 (p  0.052)
4 (n10) 3.7 0.7
Kiss et al. [7] 5 (n10) 3 (p  0.007) 0.7 (NS)
5 (n7) 14 1
Weaver et al. [57] 5 (n1411) 2.5 (p  0.0001) 1.3 (p ≤ 0.0001)
5 (n363) 5 2.3
van der Wall et al. [16] 5 (n24) 3.9 (p  0.005) 0.8 (p  0.015)
5 (n16) 6.4 1.2
aResults are provided as the number of transfusions given and represent the median
[5–7,9,10,29,31] and mean [16,25,57] number of units transfused. For studies in
which transfusions were provided in units rather than number of transfusions
([6,7,10,29] for platelets and RBCs; [10,16] for RBCs only), however, the units
were converted to numbers by dividing by 6.
bp not provided.
NA, not available; NS, not statistically signiﬁcant.
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0.2106/kg. Others have also found the number of
chemotherapy cycles to be a significant determinant of
progenitor cell yield [3,24]. Carmustine (BCNU) or busulfan
appear to have the most significant toxic effects on stem
cells; cyclophosphamide and cisplatin have intermediate
effects; and cytosine arabinoside, hydroxyurea, and 5-
ﬂuorouracil have the least impact [43].
Impact of duration of chemotherapy. Tricot et al.
observed that patients receiving more than 24 months of
chemotherapy required CD34 cell doses 5106/kg to
reach prompt hematologic recovery [33]. In that study, how-
ever, only 28% of patients received the requisite cell doses.
Fifty percent of patients receiving more than 24 months of
alkylating therapy attained platelet recovery (50109/L)
within 67 days; 75% attained platelet recovery within 94 days.
In a study by Morton et al., 89% of patients who had not
undergone prior radiotherapy or alkylating therapy achieved
an adequate cell yield (2106 CD34 cells/kg) after one
apheresis procedure and patients exposed to either therapy
benefited from repeat procedures [8]. Morton et al. deter-
mined that only four of the 23 patients receiving previous
radiotherapy or alkylating agents achieved a CD34 cell count
of 5106/kg after a single apheresis. Even after multiple
aphereses, only ﬁve of these 23 patients reached the desired
CD34 cell count. Moreover, the authors identiﬁed patients
at high risk for inadequate CD34 cell yield as those who had
undergone prior radiotherapy to the pelvis or sternum. 
In patients with multiple myeloma and Hodgkin’s dis-
ease, the need for and the timing of PBPC collection must
be considered when planning their therapeutic regimen [8].
This may include limiting the use of alkylating agents and
delaying radiotherapy until after PBPC collection. These
considerations likely may be extended to other oncology
patients. Initiation of PBPC collection should be considered
early during therapy and coordinated with the anticipated
number of chemotherapy cycles, duration of chemotherapy,
interval between chemotherapy and apheresis, need for
radiotherapy, and exposure to the more progenitor
cell–toxic drugs such as BCNU or busulfan. Finally, combi-
nations of hematopoietic growth factors such as G-CSF and
stem cell factor (SCF) may be useful in improving the efﬁ-
ciency of progenitor cell yields [44]. 
Optimization and remobilization strategies. There are
several strategies for harvesting adequate CD34 cells in
poor mobilizers. Some clinicians use large-volume (15–35 L)
aphereses collection rather than standard collection volumes
(10–14 L) [45–47]. Although it is possible to collect the
entire target CD34 cell number in one collection, large-
volume aphereses are not well tolerated by patients.
Other approaches involve remobilization strategies that
seek to stimulate increased numbers of PBPC in the periph-
eral blood. One example is the repriming of patients with
chemotherapy and growth factors (either G-CSF or GM-
CSF) and remobilizing the following week. A second strate-
gy is the use of higher doses of G-CSF (30 	g/kg/day), and
a third approach is the use of multiple cytokines such as G-
CSF combined with recombinant human SCF [40,48–50],
Table 6. Economic impact of higher CD34+ cell doses
CD34 cells/kg
Parameter 5106 1–5106 p
Days to ANC
500/La 9.3 10.1 0.0001
Days to platelet
20,000/La 10.9 14.7 0.009
Length of hospital
stay (days)a 18.5 20.2 0.053
Platelet
transfusions (units)a 2.1 3.2 0.002
G-CSF (days) 12.3 13.9 0.0001
Total costs ($) 41,550 46,460 0.005

 SD ($) 11,500 13,200
aAll results are mean values.
Modiﬁed with permission from Glaspy et al. [56].
ANC, absolute neutrophil count; G-CSF, granulocyte colony-stimulating factor;
SD, standard deviation.
Table 5. Hospitalization and antibiotic days as a function of CD34 cell
counts
106 CD34 cells/kg Number Number of
(nnumber of days days on
Author [reference]a of patients) hospitalizedb,c antibioticsb
Laport et al. [29] 1 (n18) 27 (p  0.0001) 12 (p  0.0002)
1 (n18) 37 17
Mavroudis et al. [55] 2 (n4) 39 (p  0.05) NA
1–2 (n11) 52 NA
1 (n13) 62 NA
Boroson et al. [25] 2 (n21) 24 (NS) 12 (p  0.0454)
2 (n11) 26 15
Haas et al. [5] 2.5 (n35) 20d 12d,e
2.5 (n7) 31 18
Haynes et al. [6] 2.5 (n24) 15 (p  0.02) 6 (p  0.065)
2.5 (n14) 20 10
Papadopoulos et al. [9] 2.5 (n16) 19 (p  0.065) NA
1–2.5 (n15) 20 NA
Remes et al. [10] 4 (n26) 14f (p  0.308) NA
4 (n10) 18 NA
Kiss et al. [7] 5 (n10) 15 (NS) NA
5 (n7) 16 NA
Sola et al. [32] 5 (n16) 11 (p  0.001) 6f (p  0.01)
5 (n18) 14 9f
van der Wall et al. [16] 5 (n24) 12f (NS) NA
5 (n16) 16f NA
aAll patients underwent PBPCT except for those reported in Reference 55, who
underwent BMT.
bResults for number of days hospitalized and on antibiotics are provided as median
days [5–7,9,10,29,32,55] or mean days [16,25].
cNumber of days hospitalized refers to total inpatient days of hospitalization
[5,6,9,26,30,33], days of hospitalization after transplantation [7,10,16], or inpatient
days during the ﬁrst 100 days posttransplant [55].
dStatistical signiﬁcance not provided.
eNumber of days on antibiotics speciﬁcally refers to days on i.v. antibiotics.
fResults are rounded to the nearest whole number.
NA, not available; NS, not signiﬁcant.
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recombinant human Mpl ligands [51,52], ﬂt-3 ligands [53],
or interleukin-3 receptor ligands [54].
Often, however, remobilization is not successful. The
recommended alternative is the harvesting of bone marrow
from patients during the following week. Most centers agree
that if 1106 CD34 cells/kg are harvested and infused,
engraftment delay could result. If this dose is not achieved
after 3–5 aphereses, additional procedures often have no
value and other strategies for harvesting adequate CD34
cells, as noted above, should be considered.
Economic impact of increased CD34 cell count
The impact of increased CD34 cell counts on resource
consumption also has been evaluated by examining data on
length of hospital stay and the number of days on antibiotics
for patients undergoing PBPC or bone marrow transplanta-
tion (Table 5). Data support the observation that patients
reinfused with higher stem cell doses have shorter hospital-
izations and require fewer days on antibiotics. Additional
sources of savings would include decreased cytokine use and
fewer platelet and red blood cell transfusions.
In a prospective study of patients with breast cancer
undergoing HDCT with PBPC support, Glaspy et al. col-
lected billing and resource consumption data [56]. Two
groups, those receiving 5106 CD34 cells/kg and those
receiving 1 but 5106 CD34 cells/kg, were compared.
Patients receiving the lower dose had significantly longer
neutropenia and thrombocytopenia and consumed signifi-
cantly more platelet transfusions, days in the hospital, physi-
cian services, and doses of post-HDCT filgrastim. These
results are summarized in Table 6. Using the economic data
collected during the study, the authors estimated that
patients receiving 5106 CD34 cells/kg incurred signiﬁ-
cantly higher mean post-HDCT costs than those receiving
5106 CD34 cells/kg during the recovery period by
approximately $4900. Cost savings did not include home
nursing or indirect costs (e.g., outpatient medication use
other than G-CSF) to patients and their families. These
data must be balanced against the cost of additional aphere-
sis procedures (reported at $2226 each) that may be
required to collect 5106 CD34 cells/kg. Also, the col-
lection of economic data stopped after the 100th day post-
HDCT and the full cost of outliers still requiring transfu-
sion support at that time was not measured. For these two
reasons, the estimate is likely to be lower than the true cost
savings to be realized by CD34 cell doses of 5106/kg.
Weaver et al. evaluated CD34 cell dose for 1774
patients who, in general, had stage II-IV breast cancer, lym-
phoma, myeloma, ovarian cancer, or sarcoma [57]. Costs of
resources were developed from median costs of 247 patients
undergoing transplantation in one university setting (Table
7) and doses 5106 CD34 cells/kg were compared with
doses 5106 CD34 cells/kg. The authors concluded that
implementing a CD34 cell dose of 5106 cells/kg for
patients undergoing PBPC transplantation would reduce
resource consumption for PBPC patients by approximately
$8200. It should be noted that the median CD34 cell dose
in the low dose group was 3.5106 cells/kg in this study.
This underscores the emerging realization that CD34 cell
doses higher than those historically considered adequate
may be of substantial beneﬁt to patients.
Results suggest that for CD34 cell doses 5106/kg
recovery will be delayed for some patients, resulting in
greater transfusion requirements, longer hospitalization,
increased antibiotic use and growth factor support, and
higher health care costs. As stated by Faucher et al., “Practi-
cally…the failure to reach [a] designated threshold [of
CD34 cells] does not represent a contraindication to
HDCT and transplantation but rather predicts a less attrac-
tive cost-benefit ratio, as patients will require increased
access to medical resources” [4]. Thus, a cost-beneﬁt assess-
ment is needed to determine the propriety of reinfusing
patients with doses that are less than optimal. 
REFERENCES
1 Bensinger W, Singer J, Applebaum F, Lilleby K, Longin K, Rowley S,
Clarke E, Clift R, Hansen J, Shields T: Autologous transplantation with
peripheral blood mononuclear cells collected after administration of
recombinant granulocyte stimulating factor. Blood 81:3158, 1993.
2 Bitran JD, Martinec J, Okuno T: Autologous bone marrow trans-
plantation using peripheral blood hematopoietic progenitor cells: The
total number of CD34 cells/kg predicts for hematologic engraftment.
Blood 82:288a, 1993. [abstr]
3 Chabannon C, Le Corroller AG, Faucher C, Novakovitch G, Blaise D,
Moatti JP, Maraninchi D, Mannoni P: Patient condition affects the col-
lection of peripheral blood progenitors after priming with recombinant
granulocyte colony-stimulating factor. J Hematother 4:171, 1995.
4 Faucher C, Le Corroller AG, Chabannon C, Viens P, Stoppa AM,
Bouabdallah R, Camerlo J, Vey N, Gravis G, Gastaut JA, Novakovitch G,
Mannoni P, Bardou VJ, Moatti JP, Maraninchi D, Blaise D: Autologous
transplantation of blood stem cells mobilized with ﬁlgrastim alone in 93
patients with malignancies: The number of CD34 cells reinfused is the
only factor predicting both granulocyte and platelet recovery. J Hema-
tother 5:663, 1996.
5 Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M,
Wannenmacher M, Hunstein W: Patient characteristics associated with
successful mobilizing and autografting of peripheral blood progenitor
cells in malignant lymphoma. Blood 83:3787, 1994.
6 Haynes A, Hunter A, McQuaker G, Anderson S, Bienz N, Russell NH:
Engraftment characteristics of peripheral blood stem cells mobilized
with cyclophosphamide and the delayed addition of G-CSF. Bone Mar-
row Transplant 16:359, 1995.
7 Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister
J, D’Andrea P, Ball ED: Relationship of CD34 cell dose to early and
Table 7. Cost reduction with higher CD34 cell doses
CD34 cells/kg Cost Incremental
Parameter 5106 5106 per unit ($) cost ($)
Length of hospital
stay (days)a 11b 14 2190 6570
Platelet transfusionsa 2.5b 5 500 1250
RBC transfusions 1.3b 2.3 400 400
Total cost 8220
aAll results are mean values.
bp ≤ 0.0001.
Modiﬁed with permission from Weaver et al. [57].
RBC, red blood cell.
CD34 Cell Dose
91B B & M T
late hematopoiesis following autologous peripheral blood stem cell
transplantation. Bone Marrow Transplant 19:303, 1997.
8 Morton J, Morton A, Bird R, Hutchins C, Durrant S: Predictors for
optimal mobilization and subsequent engraftment of PBPCs following
intermediate dose cyclophosphamide and G-CSF. Blood 86:408a, 1995.
[abstr]
9 Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss
RF, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS: Harvest quali-
ty and factors affecting collection and engraftment of CD34 cells in
patients with breast cancer scheduled for high dose chemotherapy and
peripheral blood progenitor cell support. J Hematother 6:61, 1997.
10 Remes K, Matinlauri I, Grenman S, Itälä M, Kauppila M, Pelliniemi
TT, Salminen E, Vanharanta R, Rajamäki A: Daily measurements of
blood CD34 cells after stem cell mobilization predict stem cell yield
and posttransplant hematopoietic recovery. J Hematother 6:13, 1997.
11 Rybka WB, Kiss JE, Lister J: Graft CD34 cell content predicts
engraftment following allogeneic and autologous hematopoietic stem
cell transplantation. Blood 84:87a, 1991. [abstr]
12 Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K,
Hazelton B, West W: Rapid and sustained hematopoietic reconstitution
by peripheral blood stem cell infusion alone following high-dose
chemotherapy. Bone Marrow Transplant 11:369, 1993.
13 Schwella N, Beyer J, Schwaner I, Heuft HG, Rick O, Huhn D, Serke S,
Siegert W: Impact of preleukapheresis cell counts on collection results
and correlation of progenitor-cell dose with engraftment after high-
dose chemotherapy in patients with germ cell cancer. J Clin Oncol
14:1114, 1996.
14 Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern
AC, Lansdorp PM, Bonadonna G, Gianni AM: Flow cytometry for clinical
estimation of circulating hematopoietic progenitors for autologous
transplantation in cancer patients. Blood 77:400, 1991.
15 Urashima M, Uchiyama H, Hoshi Y, Deguchi Y, Kamijou M, Katou Y,
Fujisawa K, Akatsuka J, Maekawa K: Prediction of engraftment after
peripheral blood stem cell transplantation by CD34-positive cells in
grafts. Acta Paediatrica Japonica 35:325, 1993.
16 van der Wall E, Richel DJ, Holtkamp MJ, Slaper-Cortenbach IC, van
der Schoot CE, Dalesio O, Nooijen WJ, Schornagel JH, Rodenhuis S: Bone
marrow reconstitution after high-dose chemotherapy and autologous
peripheral blood progenitor cell transplantation: effect on graft size.
Ann Oncol 5:795, 1994.
17 Zimmerman TM, Lee WJ, Bender JG, Mick R, Williams SF: Quanti-
tative CD34 analysis may be used to guide peripheral blood stem cell
harvests. Bone Marrow Transplant 9:439, 1995.
18 Bender JG, To LB, Williams S, Schwartzberg LS: Deﬁning a thera-
peutic dose of peripheral blood stem cells. J Hematother 1:329, 1992.
19 Reiffers J, Faberes C, Boiron J, Marit G, Foures C, Ferrer AM, Cony-
Makhoul P, Puntous M, Bernard P, Vezon G: Peripheral blood progenitor
cell transplantation in 118 patients with hematological malignancies:
analysis of factors affecting rate of engraftment. J Hematother 3:185,
1994.
20 To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D,
Ho JQ, Dart GW, Horvath N, Davy ML: Comparison of haematological
recovery times and supportive care requirements of autologous recov-
ery phase peripheral blood stem cell transplants, autologous bone mar-
row transplants and allogeneic bone marrow transplants. Bone Marrow
Transplant 9:277, 1992.
21 Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger
DD: Autologous peripheral hematopoietic stem cell transplantation
restores hematopoietic function following marrow ablative therapy.
Blood 71:723, 1988.
22 Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Fer-
rant A, Demuynck HM, Link H, Zander A, Barge A: Randomized trial of
filgrastim-mobilized peripheral blood progenitor cell transplantation
versus autologous bone-marrow transplantation in lymphoma patients.
Lancet 347:353, 1996.
23 Bensinger WI, Longin K, Applebaum F, Rowley S, Weaver C, Lilleby K,
Gooley T, Lynch M, Higano T, Klarnet J: Peripheral blood stem cells
(PBSCs) collected after recombinant granulocyte colony stimulating
factor (rhG-CSF): an analysis of factors correlating with the tempo of
engraftment after transplantation. Br J Haematol 87:825, 1994.
24 Bensinger W, Appelbaum F, Rowley S: Factors that inﬂuence collec-
tion and engraftment of autologous peripheral-blood stem cells. J Clin
Oncol 13:2547, 1995.
25 Boroson R, Brown R, Hendricks D: Hematopoietic recovery after
stem cell transplantation: impact of CD34 cell dose and method of
mobilization. Blood 84:349a, 1991. [abstr]
26 Bregni M, Siena S, Magni M, Bonadonna G, Gianni AM: Circulating
hemopoietic progenitors mobilized by cancer chemotherapy and by
rhGM-CSF in the treatment of high-grade non-Hodgkin’s lymphoma.
Leukemia 5 (Suppl 1):123, 1991.
27 Dercksen MW, Rodenhuis S, Dirkson MKA, Schaasberg WP, Baars
JW, van der Wall E, Slaper-Cortenbach IC, Pinedo HM, von dem Borne
AE, van der Schoot CE: Subsets of CD34 cells and rapid hematopoietic
recovery after peripheral-blood stem-cell transplantation. J Clin Oncol
13:1922, 1995.
28 Fraser JK, Nishikubo C, Lill MC, Emmanouilides C: CD34-positive
cell mobilization in patients treated with autologous stem cell trans-
plant for lymphoma: superior harvests in patients with primary refrac-
tory disease. Blood 88:407a, 1996. [abstr]
29 Laport GF, Zimmerman TM, Grinblatt GC: CD34 peripheral
blood stem cell (PBSC) dose inﬂuences engraftment kinetics and other
relevant clinical variables. Proc ASCO 15:969a, 1996. [abstr]
30 Magalhaes-Silverman M, Kiss J, Lembersky B: Factors affecting
engraftment in patients with metastatic breast cancer (MBC) treated
with high dose chemotherapy (HDC) and peripheral blood stem cell
(PBSC) transplant. Proc ASCO 15:969a, 1996. [abstr]
31 Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH,
Cao J, Lee JC, Hong CH: Transplantation of CD34 peripheral blood
progenitor cells after high dose chemotherapy for patients with
advanced multiple myeloma. Blood 86:390, 1995.
32 Sola C, Maroto P, Salazar R: High dose chemotherapy (HDC) and
peripheral blood stem cell (PBSC) autologous transplantation: Influ-
ence of the number of infused CD34 cells in hematopoietic recovery
and support measures required. Proc ASCO 15:538, 1996. [abstr]
33 Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson
B, Crowley J, Barlogie B: Peripheral blood stem cell transplants for mul-
tiple myeloma: identification of favorable variables for rapid engraft-
ment in 225 patients. Blood 85:588, 1995.
34 To LB, Haylock DN, Simmons PJ: The biology and clinical uses of
blood stem cells. Blood 89:2233, 1997.
35 Brecher ME, Sims L, Schmitz J, Shea T, Bentley SA: North American
multicentre study on ﬂow cytometric enumeration of CD34 hemato-
poietic stem cells. J Hematother 5:227, 1996.
36 Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I: The
ISHAGE guidelines for CD34 cell determination by ﬂow cytometry.
International Society of Hematotherapy and Graft Engineering. J
Hematother 5:213, 1996.
37 Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-
Cortenbach IC, Schaasberg WP, Pinedo HM, von dem Borne AE, van der
Schoot CE: Expression of adhesion molecules on CD34 cells: CD34
L-selectin cells predict a rapid platelet recovery after peripheral blood
stem cell transplantation. Blood 85:3313, 1995.
EJ Shpall et al.
92
38 Pecora AL, Zahos KM, Jennis A: The extent and timing of early
(CD34/CD33) hematopoietic progenitor mobilization following
chemotherapy and/or cytokine priming. Blood 88:678a, 1996. [abstr]
39 Hohaus S, Hartmut G, Ehrhardt R, Haas R: Successful autografting
following myeloablative conditioning therapy with blood stem cells
mobilized by chemotherapy plus rhG-CSF. Exp Hematol 21:508, 1993.
40 Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM,
Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece
IK: Peripheral blood progenitor cell mobilization using stem cell factor
in combination with ﬁlgrastim in breast cancer patients. Blood 90:2939,
1997.
41 Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L,
West W: An analysis of engraftment kinetics as a function of the CD34
content of peripheral blood progenitor cell collections in 692 patients
after the administration of myeloablative chemotherapy. Blood
86:3961, 1995.
42 Shepherd KM, Charles P, Sage RE: Mobilization of haemopoietic
stem cells by cyclophosphamide into the peripheral blood of patients
with haematological malignancies. Clin Lab Haematol 13:25, 1991.
43 Neben S, Hemman S, Montgomery M, Ferrara J, Mauch P, Hellman
S: Hematopoietic stem cell deﬁcit of transplanted bone marrow previ-
ously exposed to cytotoxic agents. Exp Hematol 21:156, 1993.
44 Tricot G, Jagannath S, Olson E: Mobilization of peripheral blood
progenitor cells (PBPCs) using r-metHuSCF (SCF) and/or r-metHu-
CSF (ﬁlgrastim) in heavily pretreated multiple myeloma patients. Blood
88:388a, 1996. [abstr]
45 Malachowski ME, Comenzo RL, Hillyer CD, Tiegerman KO, Berkman
EM: Large-volume leukapheresis for peripheral blood stem cell collec-
tion in patients with hematologic malignancies. Transfusion 32:732,
1992.
46 Comenzo RL, Malachowski ME, Miller KB, Erban JJ, Schenkein DP,
Desforges JF, Berkman EM: Engraftment with peripheral blood stem
cells collected by large-volume leukapheresis for patients with lym-
phoma. Transfusion 32:729, 1992.
47 Comenzo RL, Malachowski ME, Miller KB, Erban JJ, Schenkein DP,
Desforges JF, Berkman EM: Large-volume leukapheresis for collection
of mononuclear cells for hematopoietic rescue in Hodgkin’s disease.
Transfusion 35:42, 1995.
48 Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ,
Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR,
Brown SL, Nimer SD, Gabrilove J: Recombinant methionyl human stem
cell factor and ﬁlgrastim for peripheral blood progenitor cell mobiliza-
tion and transplantation in non-Hodgkin’s lymphoma patients—results
of a phase I/II trial. Blood 89:3136, 1997.
49 Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG: Increased
numbers of long-term culture-initiating cells in the apheresis product
of patients randomized to receive increasing doses of stem-cell factor
administered in combination with chemotherapy and a standard dose of
granulocyte colony-stimulating factor. Blood 88:3323, 1996.
50 Begley CG, Basser R, Mansﬁeld R, Thomson B, Parker WR, Layton J,
To B, Cebon J, Sheridan WP, Fox RM, Green MD: Enhanced levels and
enhanced clonogenic capacity of blood progenitor cells following
administration of stem cell factor plus granulocyte colony-stimulating
factor to humans. Blood 90:3378, 1997.
51 Rasko JEJ, Basser RL, Boyd J, Mansﬁeld R, O’Malley CJ, Hussein S,
Berndt MC, Clarke K, O’Byrne J, Sheridan WP, Briggs AP, Begley CG:
Multilineage mobilization of peripheral blood progenitor cells in
humans following administration of PEG-rHuMGDF. Br J Haematol
97:871, 1997.
52 Basser RL, Rasko JEJ, Clarke CK, Cebon J, Green MD, Grigg AP,
Zalcberg J, Cohen B, O’Byrne J, Menchaca DM, Fox RM, Begley CG: Ran-
domized, blinded, placebo-controlled phase I trial of pegylated recom-
binant human megakaryocyte growth and development factor with ﬁl-
grastim after dose-intensive chemotherapy in patients with advanced
cancer. Blood 89:3118, 1997.
53 Lebsack ME, McKenna HJ, Hoek JA, Hanna R, Feng A, Marashovsky
E, Hayes FA: Safety of FLT3 ligand in healthy volunteers. Blood
90:170a, 1997. [abstr]
54 DiPersio JF, Abboud CN, Schuster MW, Winter JN, Collins DM,
Santos VR, Baum CM: Phase II study of mobilization of PBSC by
administration of daniplestim (SC-55494) and G-CSF in patients with
breast cancer or lymphoma. Proc ASCO 16:87a, 1997. [abstr]
55 Mavroudis D, Read E, Cotter-Fox M, Couriel D, Molldrem J, Carter C,
Yu M, Dunbar C, Barrett J: CD34 cell dose predicts survival, posttrans-
plant morbidity, and rate of hematologic recovery after allogeneic mar-
row transplants for hematologic malignancies. Blood 88:3223, 1996.
56 Glaspy J, Lu ZJ, Wheeler C: Economic rationale for infusing opti-
mal numbers of CD34 cells in peripheral blood progenitor cell trans-
plants (PBPCT). Blood 90 (Suppl 1):370a, 1997. [abstr]
57 Weaver CH, Birch R, Schulman KA: Effect of cell dose on resource
utilization in patients undergoing transplant with peripheral blood pro-
genitor cells. Blood 90 (Suppl 1):370a, 1997. [abstr]
